Lannett (NYSE:LCI) is scheduled to release its earnings data after the market closes on Wednesday, February 7th. Analysts expect Lannett to post earnings of $0.85 per share for the quarter.
Lannett (NYSE:LCI) last announced its earnings results on Monday, November 6th. The company reported $0.60 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.08. Lannett had a net margin of 6.67% and a return on equity of 18.23%. The business had revenue of $155.00 million during the quarter, compared to analysts’ expectations of $153.62 million. During the same quarter in the prior year, the company posted $0.77 earnings per share. The firm’s revenue was down 4.1% on a year-over-year basis. On average, analysts expect Lannett to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Lannett (NYSE LCI) opened at $20.05 on Tuesday. Lannett has a 1-year low of $14.90 and a 1-year high of $30.35. The company has a market cap of $755.88, a price-to-earnings ratio of 17.90, a P/E/G ratio of 1.31 and a beta of 2.51. The company has a current ratio of 2.52, a quick ratio of 1.90 and a debt-to-equity ratio of 1.44.
Several brokerages recently commented on LCI. ValuEngine cut shares of Lannett from a “buy” rating to a “hold” rating in a report on Friday. Oppenheimer restated a “hold” rating on shares of Lannett in a report on Monday, December 11th. Zacks Investment Research cut shares of Lannett from a “buy” rating to a “hold” rating in a report on Wednesday, December 13th. Goldman Sachs Group began coverage on shares of Lannett in a report on Wednesday, January 24th. They set a “neutral” rating and a $21.00 target price for the company. Finally, BMO Capital Markets increased their target price on shares of Lannett from $20.00 to $22.00 and gave the stock a “market perform” rating in a report on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. Lannett presently has an average rating of “Hold” and an average price target of $23.17.
In other Lannett news, major shareholder David Farber sold 9,816 shares of the stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $30.05, for a total value of $294,970.80. Following the completion of the sale, the insider now owns 4,190,169 shares in the company, valued at $125,914,578.45. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Arthur P. Bedrosian sold 7,422 shares of the stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $25.20, for a total transaction of $187,034.40. Following the completion of the sale, the chief executive officer now owns 679,001 shares of the company’s stock, valued at approximately $17,110,825.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 140,000 shares of company stock valued at $3,681,091. Corporate insiders own 14.72% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Lannett (LCI) Scheduled to Post Earnings on Wednesday” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/06/lannett-lci-scheduled-to-post-earnings-on-wednesday.html.
Lannett Company Profile
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.